drugset / Trial / NCT01970046
A Phase III Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes
RandomizedParallel-groupQuadruple-blindTreatment
Summary
SP2086 is a new dipeptidy1 peptidase(DPP)-4 inhibitors. This study aims to evaluate the efficacy and safety of SP2086 in combination therapy with Metformin in patients with Type 2 Diabetes Mellitus in Metformin monotherapy Who Have Inadequate Glycemic Control
Timeline
- Start
- 2013-04
- Primary completion
- 2014-01
- Completion
- 2015-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Retagliptin | Small molecule | 50 mg | — |
| Comparator | Metformin | Small molecule | 500 mg | — |